Friday, December 12, 2025

Company Overview:

MYM Nutraceuticals Inc. is an innovative company focused on the global growth of Cannabis and hemp.  To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors.  MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE:MYM) (OTC:MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY).

[stock_market_chart symbol=”MYM.CN” range=”1y” settings='{“primaryChartType”:”smoothedLine”,”width”:”100%”,”height”:”350px”,”marginTop”:0,”marginBottom”:0,”marginLeft”:10,”marginRight”:10,”primaryPanelTitle”:”Price”,”secondaryPanelTitle”:”Volume”,”fontSize”:13,”color”:”#383838″,”primaryLineColor”:”#000″,”primaryLineColorAlpha”:0.15,”secondaryLineColor”:”#000″,”secondaryLineColorAlpha”:0.15,”backgroundColor”:”#fff”,”gridColor”:”#e0e0e0″,”gridAlpha”:0.8,”cursorColor”:”#ba0000″,”cursorAlpha”:0.8,”scrollbarBackgroundColor”:”#fff”,”scrollbarSelectedBackgroundColor”:”#000″,”scrollbarGraphFillColor”:”#000″,”scrollbarSelectedGraphFillColor”:”#000″,”primaryLineThickness”:0,”secondaryLineThickness”:0,”gridThickness”:0,”precision”:2,”thousandsSeparator”:”,”,”decimalSeparator”:”.”,”usePrefixes”:false,”mouseWheelZoomEnabled”:false,”cursorEnabled”:false,”exportEnabled”:false,”scrollbarEnabled”:false,”legendEnabled”:false,”periods”:”1W,1M,6M,YTD,1Y,ALL”,”defaultPeriod”:”1y”}’]

Key Share Information:

Current Share Price$0.12
Market Capitalization (in Millions)$15.09
Last Quarter (Share Data)2/28/2019
Shares Outstanding (in Millions)125.72
Options (in Millions)9.11
Warrants (in Millions)14.09
Fully Diluted (in Millions)148.91
<th<tr<td<tr<td<tr<td<tr<td<tr<td<tr<td<tr<td
<!DOCTYPEhtml><metaname="google"content="notranslate"><metaname="viewport"content="target-densitydpi=device-dpi,user-scalable=1,minimum-scale=1,maximum-scale=2.5,initial-scale=1,width=device-width"><metahttp-equiv="X-UA-Compatible"content="IE=edge;"><metaname="referrer"content="origin">MYM</td><td class="column-11">Nutraceuticals</td><td class="column-12">-</td><td class="column-13">Google</td><td class="column-14">Drive<linkrel="shortcuticon"href="//ssl.gstatic.com/docs/spreadsheets/favicon3.ico"><linkhref='/static/spreadsheets2/client/css/2968578022-waffle_k_ltr.css'type='text/css'rel='stylesheet'nonce="Fw9E7jRvoxHul7G8hNScZg"><styletype="text/css"nonce="Fw9E7jRvoxHul7G8hNScZg">
html{overflow:visible;}
#sheets-viewport{overflow:auto;}
#sheets-viewport.widget-viewport{overflow:hidden;}
.grid-container{overflow:visible;background:white;}
.grid-table-container{overflow:visible;}
#top-bar{
margin:0;
overflow:hidden;
}
#top-bar{
border-bottom:1pxsolid#ccc;
padding:6px6px0;
}
#doc-title{padding-bottom:5px;}
#doc-title.name{font-size:15px;}
#sheet-menu{
font-size:13px;
margin:6px00;
padding:005px;
}
#sheet-menuli{
display:inline;
list-style-type:none;
margin:0;
padding:5px8px;
}
#sheet-menuli.active{
background-color:#fff;
font-weight:bold;
border:1pxsolid#999;
}
#top-bar#sheet-menuli.active{
border-bottom:0;
}
#sheet-menua,#sheet-menua:visited{color:#07c;}
#footer{
background:#f0f0f0;
border-top:1px#cccsolid;
border-bottom:1px#cccsolid;
font-size:13;
padding:10px10px;
}
.dash{
padding:06px;
}
.ritz.wafflea{color:inherit;}.ritz.waffle.s1{background-color:#ffffff;text-align:center;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px3px2px3px;}.ritz.waffle.s0{background-color:#ffffff;text-align:left;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px3px2px3px;}<scripttype="text/javascript"nonce="pV1eZhB8Boz+dAbXLifK1Q">
varactiveSheetId;
functionswitchToSheet(id){
if(document.getElementById('sheet-menu')){
document.getElementById('sheet-button-'+activeSheetId)
.className='';
document.getElementById('sheet-button-'+id).className='active';
}
document.getElementById(activeSheetId).style.display='none';
document.getElementById(id).style.display='';
activeSheetId=id;
//posObjs()isdefinedinembeddedObjectJs(seeEmbeddedObjectHtmlBuilder.java)
posObjs();
returnfalse;
}
functioninit(){
varoptPageSwitcher;
functionresize(){
varoptMobileWebHeader=document.getElementById('docs-ml-header-id');
varoptTopBar=document.getElementById('top-bar');
varoptFooter=document.getElementById('footer');
varsheetsViewport=document.getElementById('sheets-viewport');
if(optMobileWebHeader){
sheetsViewport.style.marginTop=optMobileWebHeader.offsetHeight+
(optTopBar?optTopBar.offsetHeight:0)+'px';
}
varadjustedHeight=window.innerHeight-
(optTopBar?optTopBar.offsetHeight:0)-
(optFooter?optFooter.offsetHeight:0);
varadjustedWidth=window.innerWidth;
sheetsViewport.style.width=(adjustedWidth+'px');
sheetsViewport.style.height=(adjustedHeight+'px');
if(optPageSwitcher){
optPageSwitcher.resize(adjustedWidth,adjustedHeight);
}
}
resize();
window.onresize=resize;
varcurrentUrl=window.location.href;
varnewUrl=currentUrl.replace('?sle=true&','?');
newUrl=newUrl.replace('?sle=true','');
newUrl=newUrl.replace('&sle=true&','&');
newUrl=newUrl.replace('&sle=true','');
window.history.replaceState(null,'',newUrl);
}
<scriptnonce="pV1eZhB8Boz+dAbXLifK1Q">_docs_flag_initialData={"docs-mwid":false,"docs-smheo":false,"info_params":{"includes_info_params":true},"ilcm":{"eui":"ADFN-ctoHzWx9j47QMwHvC0oA13I7GJCkxvKJTCVQTTUU5ZYqxEV1bNi0EwGJn7mYxWxdHBMXlSK","je":1,"sstu":1623926851831000,"si":"CNSQlPm-nvECFVaGqwcd6RgGyw","gsc":0,"ei":[5707711,5703186,5731094,5708862,5705301,5714628,5707197,5728103,5737700,5700019,5713152,5723284,5717118,5704063,5711808,5710677,5709709,5737898,5733710,5714961,5715515,5709892,5707385,5708480,5709381,5707047,5715399,5715637,5719170,5706133,5714843,5716141,5738168,5703913,5723871,5712352,5702767,5707943,5702912,5710637,5711708,5711850,5720479,5737401,5720568,5725052,5722301,5712033,5704621,5704883,5700559,5721815,5719212,5707609,5710645,5717949,5713207,5711471,5739056,5701903,5724085,5702135,5708574,5721004,5708886,5733973,5706601,5733570,5737254,5713227,5728335,5732963,5725300,5725338,5720788,5713681,5705777,5714796,5712469,5716149,5700884,5714326,5724916,5709476,5711765,5713195,5728567,5716028,5704144,5720487,5735134,5715364,5707986,5720483,5710746,5706169,5711550,5712929,5720925,5711099,5721764,5704641,5711155,5720595,5728475,5702849,5719535,5713597,5714322,5720516,5717161,5713223,5707204,5705040,5701034,5707856,5711012,5703837,5730285,5713049,5712909,5735509,5714674,5702445,5714967,5734352,5713605,5710476,5711957,5720714,5703591,5727257,5724896,5708974,5706933,5710938,5724533,5703027,5729546,5712905,5711297,5722346,5712525,5710933,5713542,5728515,5707445,5710542,5715641,5702785,5712298,5708870,5719527,5714330,5735281,5728083,5711685,5722409,5715222,5727901,5731530,5719462,5709661,5727063,5721344,13702623,5706069,5710893,5712211,5731412,5712477,5703839,5711826,5717070,5713191,5730290,5727853,5716457,5702936,5705223,5706270,5731783,5711524,5713554,5707819,5703022,5703815,5703182,5719482,5712373,5711769,5725742,5737153,5734571,5705493,5720060,5700422,5721012,5719531,5714839,5726110,5705581,5712913,5709357,5735670,5722370,5719651,5711230,5704581,5728945,5711889,5715246,5725511,5727042,5712635,5707425,5706523,5721361,5719502,5700446,5728807,5722189,5719418,5706661,5734994,5722567,5714445,5710692,5736924,5714550,5713333,5701650,5726190,5703762,5721307,5726595,5714310,5707137,5712473,5715824,5709447,5730867,5705649,5716416,5703259,5738433,5735806,5709085,5713211,5701594,5723679,5729072,5706007,5706751,5729206,5716145,5713657,5707657,5735630,5723365,5727624],"crc":0,"cvi":[]},"drive_url":"//drive.google.com?usp\u003dsheets_web","docs-ehr":true,"docs-sup":"/spreadsheets"};_docs_flag_cek='';if(window['DOCS_timing']){DOCS_timing['ifdld']=newDate().getTime();}<scriptnonce="pV1eZhB8Boz+dAbXLifK1Q">document.addEventListener('DOMContentLoaded',init);<bodyclass="docs-gm"><divid="top-bar"><divid="doc-title"><spanclass="name">MYMNutraceuticals:KeyShareInfo2<divid="sheets-viewport"><divid="1294638516"style="display:none;position:relative;"dir="ltr"><divclass="ritzgrid-container"dir="ltr"><tableclass="waffle"cellspacing="0"cellpadding="0">
class="row-headerfreezebar-origin-ltrheader-shimrow-header-shim"><thid="1294638516C0"style="width:191px;"class="header-shim"><thid="1294638516C1"style="width:100px;"class="header-shim">
style="height:20px"><thid="1294638516R0"style="height:20px;"class="row-headers-backgroundrow-header-shim"><divclass="row-header-wrapper"style="line-height:20px">1<tdclass="s0">EnterpriseValue(inMIllions)class="s1">$14.24
style="height:20px"><thid="1294638516R1"style="height:20px;"class="row-headers-backgroundrow-header-shim"><divclass="row-header-wrapper"style="line-height:20px">2<tdclass="s0">TTMRevenueclass="s1">$1.78
style="height:20px"><thid="1294638516R2"style="height:20px;"class="row-headers-backgroundrow-header-shim"><divclass="row-header-wrapper"style="line-height:20px">3<tdclass="s0">TTMGrowthMargin%class="s1">65.27%
style="height:20px"><thid="1294638516R3"style="height:20px;"class="row-headers-backgroundrow-header-shim"><divclass="row-header-wrapper"style="line-height:20px">4<tdclass="s0">TTMOperatingExpensesclass="s1">$16.26
style="height:20px"><thid="1294638516R4"style="height:20px;"class="row-headers-backgroundrow-header-shim"><divclass="row-header-wrapper"style="line-height:20px">5<tdclass="s0">TTMOCFclass="s1">-$8.63
style="height:20px"><thid="1294638516R5"style="height:20px;"class="row-headers-backgroundrow-header-shim"><divclass="row-header-wrapper"style="line-height:20px">6<tdclass="s0">P/STTMclass="s1">8.47
style="height:20px"><thid="1294638516R6"style="height:20px;"class="row-headers-backgroundrow-header-shim"><divclass="row-header-wrapper"style="line-height:20px">7<tdclass="s0">P/S(LastQuarterRunRate)class="s1">#DIV/0!
<divid="footer">Publishedby<atarget="_blank"title="LearnmoreaboutGoogleSheets"href="https://docs.google.com/spreadsheets/?usp=sheets_web">GoogleSheets<spanclass="dash">–<ahref="https://docs.google.com/abuse?id=AKkXjoxJPPdT2XZQJ9j1xk56iAncfZHswcfOdDDCv4pDyGeDPRtPlG4JrPFvJQk1Nj2IigePBFtgXVU3uPjrW-o:0">ReportAbuse<spanclass="dash">–Updatedautomaticallyevery5minutes
<scripttype="text/javascript"nonce="pV1eZhB8Boz+dAbXLifK1Q">activeSheetId='1294638516';switchToSheet('1294638516');

Key Balance Sheet Information (in Millions $CAD):

CYQ4'16CYQ1'17CYQ2'17CYQ3'17CYQ4'17CYQ1'18CYQ2'18CYQ3'18CYQ4'18CYQ1'19
Cash$0.11$0.32$0.55$0.27$2.04$10.11$6.63$1.74$0.91$1.72
Biological Assets
Inventory$0.04$0.03$0.06$0.10$1.06$1.11$0.81$0.77
Total Assets$0.13$0.49$1.77$2.12$6.62$20.45$21.11$22.50$20.27$20.04
Net Tangible Assets$0.12$0.48$0.87$1.05$4.99$16.89$17.22$18.61$17.17$16.94
Intangibles/Goodwill$0.00$0.00$0.90$1.07$1.63$3.56$3.89$3.89$3.10$3.10
Total Liabilities$0.42$0.35$0.26$0.25$0.57$1.28$1.20$2.95$1.16$0.87

Key Operating Items (Quarterly in Millions $CAD):

CYQ4'16CYQ1'17CYQ2'17CYQ3'17CYQ4'17CYQ1'18CYQ2'18CYQ3'18CYQ4'18CYQ1'19
Revenue$0.14$0.28$0.40$0.48$1.78
Change in Fair Value of Biologial Assets
Gross Margin$0.06$0.19$0.25$0.40$1.16
Marketing and Sales
Investor Relations$0.00$0.01$0.02$0.12$0.32$0.58$1.570.230.34$0.43
Total Operating Expenses$0.04$0.10$0.88$0.79$1.25$2.20$6.782.732.78$3.98
Operating Cash Flow (Quarterly)-$0.03-$0.21-$0.43-$1.09-$1.60-$3.75-4.08-$0.80
Investing Cash Flow (Quarterly)-$0.07$0.02-$1.70-$2.70-$1.88-1.61-$0.03
Financing Cash Flow (Quarterly)$0.00$0.48$0.64$4.56$12.36$2.154.87$1.64

Listing Statement

Video Articles

Why Canada Has So Few Projects That Can Be Built Before 2030 | Dan Wilton – First Mining

Guanajuato Silver: Q3 Results Overshadowed By Silver Ripping

I Went to See the Highest Grade Silver on Earth | Nord Precious Metals

Recommended

Steadright Locks Up Goundafa Polymetallic Mine Under Binding MOU

Emerita Resources Awards Contract For Pre-Feasibility Study On Iberian Belt West Project